Registered Tanzania · TMDA

Oxydihy 20%

Oxytetracycline

TAN 23 VM 0213 Solution for Injection INN generic

What it does

Oxytetracycline is an antibiotic used to treat various bacterial infections.

Commonly used for: bacterial infections, acne, respiratory infections, urinary tract infections

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
TAN 23 VM 0213
Registration date
2023-03-27
Expiry date
2028-03-26
Status
Registered/Compliant
Active ingredient
Oxytetracycline
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
-
Country of origin
-

Source: Tanzania Medicines and Medical Devices Authority · fetched 2026-03-11 23:49:02 · updated 2026-09-14 03:00:45

Drug Interactions

8
Check interactions

Pharmacodynamic Warnings

Oxytetracycline appears in TABLE 1: Drugs that cause hepatotoxicity

Severe (1)

Tetracyclines - decreases absorption

Strontium is predicted to decrease the absorption of tetracyclines. Avoid. Theoretical Sucralfate

Severe Theoretical

Moderate (3)

Lithium - increases risk of lithium toxicity

Tetracyclines are predicted to increase the risk of lithium toxicity when given with lithium. Avoid or adjust dose.

Moderate Anecdotal

Tetracyclines - decreases concentration

Fosphenytoin is predicted to decrease the concentration of tetracyclines (doxycycline). Adjust dose.

Moderate Theoretical

Tetracyclines - decreases exposure

Rifampicin modestly decreases the exposure to tetracyclines (doxycycline). Adjust dose.

Moderate Study

Unknown (4)

Tetracyclines - decreases exposure

Mitotane is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

Rifampicin is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Study

Tetracyclines - decreases exposure

St John's wort is predicted to decrease the exposure to tetracyclines (eravacycline). Adjust eravacycline dose, p. 625.

Unknown Theoretical

Tetracyclines - decreases absorption

Oralzincispredictedtodecreasetheabsorptionof tetracyclines.Separateadministrationby2to3hours. oTheoretical https://www.facebook.c (Books-Courses-Medic

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Tanzania Medicines and Medical Devices Authority (Tanzania). Always consult a qualified healthcare professional before using any medication.

About this medicine

Oxytetracycline is an antibiotic used to treat various bacterial infections.

What it treats

  • bacterial infections
  • acne
  • respiratory infections
  • urinary tract infections

How it works

It works by stopping the growth of bacteria, helping to eliminate the infection.

Who it's for

It is for adults and children over the age of 12 who have specific bacterial infections.

Drug class

Tetracyclines

Cautions

  • • Avoid use with other medications that can harm the liver.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Oxytetracycline

BNF-referenced

Oxytetracycline is a broad-spectrum antibiotic belonging to the tetracycline class. It is effective against a variety of bacterial infections, including those caused by Chlamydia, Rickettsia, and Mycoplasma. This medication works by inhibiting protein synthesis in bacteria, making it a vital option in treating susceptible infections. Its use is cautioned in pediatric populations due to potential adverse effects on bone and dental development.

Indications

  • Bacterial infections (e.g. Chlamydia, Rickettsia, Mycoplasma)
  • Acne
  • Prophylaxis of asymptomatic meningococcal carrier state (not recommended)

Dosage

Adults: For adult patients, the typical dosage of oxytetracycline for susceptible infections is 100 mg twice daily for 5 days. For other conditions, such as acne, the dosage may be 500 mg twice daily, usually for a duration of 6 to 12 weeks, with the possibility of repeating the course intermittently.

Mechanism of action

Oxytetracycline exerts its antibacterial effects by binding to the 30S ribosomal subunit of bacteria, inhibiting the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This action prevents the synthesis of proteins essential for bacterial growth and replication, leading to the bacteriostatic effect of the drug.

Pharmacodynamics

The pharmacodynamics of oxytetracycline involve its ability to inhibit bacterial protein synthesis, which is critical for the growth and reproduction of bacteria. The drug demonstrates a broad spectrum of activity against both Gram-positive and Gram-negative organisms, as well as some atypical pathogens. Its effectiveness can be influenced by the presence of tetracycline resistance mechanisms in certain bacterial strains.

Pharmacokinetics

Oxytetracycline is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 1-2 hours after oral administration. It has a relatively long half-life of about 8-10 hours, allowing for twice-daily dosing. The drug is widely distributed in body tissues and fluids, including the liver, kidneys, and lungs, but is less effective in central nervous system infections due to limited penetration. It is primarily excreted via urine, and dosage adjustments may be necessary in patients with renal impairment.

Contra-indications

  • Children under 12 years due to deposition in growing bone and teeth, causing staining and occasionally dental hypoplasia

Adverse effects

  • Gastrointestinal disturbances
  • Photosensitivity
  • Dental discoloration
  • Hepatotoxicity
  • Renal impairment
  • Skin reactions including rash and urticaria
  • Ataxia
  • Hearing impairment
  • Colitis
  • Systemic lupus erythematosus exacerbation

Interactions

  • Antacids and supplements containing calcium, magnesium, or iron may reduce absorption
  • Oral contraceptives may be less effective
  • Other tetracyclines
  • Warfarin (may increase anticoagulant effect)

Precautions

  • Use with caution in patients with renal impairment
  • Monitor for hepatic toxicity in long-term use
  • Patients should be advised to avoid excessive sunlight exposure
  • Discontinue if systemic lupus erythematosus develops or worsens

Pregnancy

Oxytetracycline is contraindicated during pregnancy due to potential harm to fetal development, particularly affecting bone and dental health.

Breast-feeding

Use with caution; oxytetracycline is excreted in breast milk and may affect the infant's dental health.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Oxytetracycline 250 mg tablets
  • Oxytetracycline oral suspension
  • Oxytetracycline oral solution
BNF 85 (British National Formulary) p.646 BNF for Children 2019-2020 p.389 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Oxytetracycline

PubChem CID 54675779

Molecular formula: C22H24N2O9

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.